Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. Reply

N Engl J Med. 2024 Oct 24;391(16):1555-1556. doi: 10.1056/NEJMc2411471.
No abstract available

Publication types

  • Letter
  • Comment